The transcription factor NFATc2 controls IL-6–dependent T cell activation in experimental colitis

B Weigmann, HA Lehr, G Yancopoulos… - The Journal of …, 2008 - rupress.org
B Weigmann, HA Lehr, G Yancopoulos, D Valenzuela, A Murphy, S Stevens, J Schmidt
The Journal of experimental medicine, 2008rupress.org
The nuclear factor of activated T cells (NFAT) family of transcription factors controls calcium
signaling in T lymphocytes. In this study, we have identified a crucial regulatory role of the
transcription factor NFATc2 in T cell–dependent experimental colitis. Similar to ulcerative
colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-induced chronic
intestinal inflammation. Furthermore, NFATc2 deficiency suppressed colitis induced by
oxazolone administration. This finding was associated with enhanced T cell apoptosis in the …
The nuclear factor of activated T cells (NFAT) family of transcription factors controls calcium signaling in T lymphocytes. In this study, we have identified a crucial regulatory role of the transcription factor NFATc2 in T cell–dependent experimental colitis. Similar to ulcerative colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-induced chronic intestinal inflammation. Furthermore, NFATc2 deficiency suppressed colitis induced by oxazolone administration. This finding was associated with enhanced T cell apoptosis in the lamina propria and strikingly reduced production of IL-6, -13, and -17 by mucosal T lymphocytes. Further studies using knockout mice showed that IL-6, rather than IL-23 and -17, are essential for oxazolone colitis induction. Administration of hyper-IL-6 blocked the protective effects of NFATc2 deficiency in experimental colitis, suggesting that IL-6 signal transduction plays a major pathogenic role in vivo. Finally, adoptive transfer of IL-6 and wild-type T cells demonstrated that oxazolone colitis is critically dependent on IL-6 production by T cells. Collectively, these results define a unique regulatory role for NFATc2 in colitis by controlling mucosal T cell activation in an IL-6–dependent manner. NFATc2 in T cells thus emerges as a potentially new therapeutic target for inflammatory bowel diseases.
rupress.org